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The German government’s global health strategy 
a strategy also to support research and development
for neglected diseases?
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Neglected tropical infectious diseases as well as rare diseases are characterized by structural research and
development (R&D) deficits. The market fails for these disease groups. Consequently, to meet public health
and individual patient needs, political decision makers have to develop strategies at national and international
levels to make up for this R&D deficit. The German government recently published its first global health
strategy. The strategy underlines the German government’s commitment to strengthening global health
governance. We find, however, that the strategy lacks behind the international public health endeavors for
neglected diseases. It fails to make reference to the ongoing debate on a global health agreement. Neither does
it outline a comprehensive national strategy to promote R&D into neglected diseases, which would integrate
existing R&D activities in Germany and link up to the international debate on sustainable, needs-based R&D
and affordable access. This despite the fact that only recently, in a consensus-building process, a National Plan
of Action for rare diseases was successfully developed in Germany which could serve as a blueprint for a similar
course of action for neglected diseases. We recommend that, without delay, a structured process be initiated in
Germany to explore all options to promote R&D for neglected diseases, including a global health agreement.
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I
n July 2013, the German federal government pub-
lished its first global health strategy, entitled ‘Shaping
Global Health  taking joint action  embracing
responsibility’ (1). The strategy underlines the impor-
tance of strengthening health systems worldwide, of
intersectoral cooperation, of involving health research
and health industries to promote global health, and of
strengthening global health governance. Some aspects,
however, which are quite prominent on the international
global health agenda, are conspicuously missing in the
German strategy.
The strategy is built on five targeted measures, of which
the last one is aimed at ‘Strengthening the global health
architecture’. In this context, the document underlines the
German commitment to promoting global health govern-
ance. It highlights the core responsibility of WHO to set
binding norms (2). Indeed, in the past decade, WHO
commissions on macroeconomics and health, on intellec-
tual property rights, innovation and public health, and on
social determinants and health generated evidence on
global health inequalities and framed relevant recommen-
dations (35). A debate gained momentum about devel-
oping, in the framework of WHO (6, 7), a legal instrument
which would promote needs-based medical research and
development (R&D) and grant equitable access to medi-
cines. Financial commitments of contracting states would
enable sustainable funding flows for medical R&D. This
funding sustainability is lacking in areas of little economic
interest for the pharmaceutical industry, such as neglected
tropical diseases (8). To ensure equitable access to innova-
tive products, R&D costs would be de-linked from product
prices, and prize funds would be awarded to developers of
innovative products (9). Advocates for this approach
predicted it to significantly contribute to reducing global
health inequalities while critics feared increasing bureau-
cracy and inefficiency (1019). In April 2012, the WHO
Consultative Expert Working Group on R&D: Financing
and Coordination (CEWG) proposed that negotiations
be taken up for a binding global health agreement with
a focus on health needs of developing countries (9).
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The World Health Assembly (WHA) did not follow the
recommendations of the CEWG; instead, the Assembly
urged WHO member states to review the CEWG’s Final
Report at national levels and to develop proposals on the
recommendations contained therein (20).
Lacking behind the global health debates
Against the background of these topical developments,
one could have assumed that the German government’s
global health strategy, and particularly its target measure
on global health governance, would make reference to
the recommendations and the follow-up activities to the
WHO CEWG Report (7, 21, 22) and to the debate on a
global health agreement (17, 19, 23). It was the realization
that health inequalities exist and that they are largely
avoidable which triggered the ongoing debate about a
global health agreement and the proposals to improve
global health architecture. Structural R&D deficits for
neglected diseases are a highly visible manifestation
of such inequality. However, no mention is made in the
German strategy of an ongoing national opinion-forming
process or a position regarding the development of this
agreement. Instead, the German concept focuses on the
contribution Germany is making to existing structures,
such as the European & Developing Countries Clinical
Trials Partnership (EDCTP) or the International Health
Partnership (IHP). The concept underlines the assumingly
important role which German pharmaceutical industry
plays in global health by providing medicines and expertise
to building research capacity in developing countries.
No mention is made of the World Trade Organization
(WTO), which plays a prominent role in public health and
in the debate about equitable access to medicines, espe-
cially for poverty-related diseases (24). It is explicitly
stated in the strategy that the German government is
‘against introducing an additional organization or initia-
tive in the health sector with the same mandates and tasks
as existing organizations and initiatives and attempts,
within its powers, to prevent this’ (1).
Missed opportunities
Surprisingly, a few months after the release of the strategy,
it was the German Association of Research-Based Phar-
maceutical Companies (vfa), and not the German gov-
ernment, which invited representatives of the political,
economic, industry, academic and civil society sector to
establish a German network against neglected tropical
diseases of poverty (25). So not only does the German
government’s strategy fail to refer to a very topical issue in
global health governance and global health architecture.
The German government should also not leave it in the
hands of the pharmaceutical industry to take the lead in
organizing a national network to combat neglected diseases.
Such an initiative reflects the intersectoral cooperation,
which is one targeted measure of the German global
health strategy. One would thus assume that it should have
been launched and chaired by the German government,
and not by the private sector. All the more so, since
a similar process was initiated several years ago which
could serve as a blueprint.
A call for action
In 2010, the German Ministries of Health and of
Education and Research and the Alliance for Chronic
Rare Diseases founded the National Action League for
People with Rare Diseases. In a 3-year consensus-building
process, the League developed a National Plan of Action
with 52 policy recommendations (26). Rare diseases are
characterized by structural R&D deficits, as are neglected
diseases. They are not poverty-associated diseases, and the
challenges which patients, researchers and political deci-
sion-makers face, are very different (27). Still, in response
to the WHA’s Resolution of 2012 (20) in which it urged
member states ‘to hold national level consultations among
all relevant stakeholders, in order to discuss the CEWG
report and other relevant analyses, resulting in concrete
proposals and actions’, the German federal government
could by now have initiated a similar process for neglected
diseases and referred to it in its global health strategy.
This should happen now. The German government has
undertaken considerable efforts to promote R&D into
neglected diseases (28). A national action plan for neglected
diseases, which would bring together actors from the public,
the private, and the civil society sector, could integrate these
activities and ensure their sustainability. Such a plan would
have to be part of a comprehensive national strategy for
promoting global health architecture. Devising it would
further strengthen the opinion-forming process regarding
the position of the German government on the development
of a global health agreement.
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